Voyager's new gene therapy targets amyloid plaques in Alzheimer's disease
FierceBiotech - 04-Aug-2023New treatment approach could be more effective in lowering the risk of serious side effects
Join the club for FREE to access the whole archive and other member benefits.
Writer at Fierce Biotech, covering developments in basic science research and early-stage drug development.
Helen Floersh is a creative, enterprising multimedia journalist and communications professional with an academic background in neuroscience and pharmacology. She is a writer and host at multiplatform education channel Wisecrack and a product manager at True, a social media company. She is currently working as a contributing writer at Fierce Biotech, covering developments in basic science research and early-stage drug development. She was previously a full-time reporter at the San Fernando Valley Business Journal, where she wrote digital and print stories about the local business community.
Helen graduated with a bachelors degree in Neuroscience from Rhodes College. She also completed her masters in Pharmacology from Tulane University School of Medicine and in Broadcast Journalism from University of Southern California.
Visit website: https://helenfloersh.com/index.html
See also
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 17-Sep-2023
New treatment approach could be more effective in lowering the risk of serious side effects